{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:04:33Z","timestamp":1793318673819,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ageing Research Reviews"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.arr.2021.101339","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T19:03:57Z","timestamp":1617649437000},"page":"101339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":227,"special_numbering":"C","title":["Effects of monoclonal antibodies against amyloid-\u03b2 on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5335-8346","authenticated-orcid":false,"given":"Konstantinos I.","family":"Avgerinos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Ferrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Kapogiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arr.2021.101339_bib0005","doi-asserted-by":"crossref","first-page":"146","DOI":"10.14283\/jpad.2020.24","article-title":"The future of anti-amyloid trials","volume":"7","author":"Aisen","year":"2020","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101339_bib0010","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.trci.2019.06.005","article-title":"Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer\u2019s disease clinical trials","volume":"5","author":"Andrews","year":"2019","journal-title":"Alzheimer Dement."},{"key":"10.1016\/j.arr.2021.101339_bib0015","series-title":"UPDATE ON FDA ADVISORY COMMITTEE\u2019S MEETING ON ADUCANUMAB IN ALZHEIMER\u2019S DISEASE","author":"Biogen","year":"2020"},{"key":"10.1016\/j.arr.2021.101339_bib0020","series-title":"BIOGEN AND EISAI ANNOUNCE FDA\u2019S 3-MONTH EXTENSION OF REVIEW PERIOD FOR THE BIOLOGICS LICENSE APPLICATION FOR ADUCANUMAB","author":"Biogen","year":"2021"},{"key":"10.1016\/j.arr.2021.101339_bib0025","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005593","article-title":"Cholinesterase inhibitors for Alzheimer\u2019s disease","author":"Birks","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.arr.2021.101339_bib0030","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","article-title":"Alzheimer\u2019s disease","volume":"368","author":"Blennow","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.arr.2021.101339_bib0035","series-title":"Independent Subgroups within a Study, Introduction to Meta\u2010analysis","author":"Borenstein","year":"2009"},{"key":"10.1016\/j.arr.2021.101339_bib0040","series-title":"Random-Effects Model, Introduction to Meta\u2010Analysis","author":"Borenstein","year":"2009"},{"key":"10.1016\/j.arr.2021.101339_bib0045","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","article-title":"A power primer","volume":"112","author":"Cohen","year":"1992","journal-title":"Psychol. Bull."},{"key":"10.1016\/j.arr.2021.101339_bib0050","series-title":"A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer\u2019s Disease (AD)","author":"CREAD1","year":"2020"},{"key":"10.1016\/j.arr.2021.101339_bib0055","series-title":"A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer\u2019s Disease (AD) (CREAD 2)","author":"CREAD2","year":"2020"},{"key":"10.1016\/j.arr.2021.101339_bib0060","article-title":"Alzheimer\u2019s disease drug development pipeline: 2020","volume":"6","author":"Cummings","year":"2020","journal-title":"Alzheimer Dement."},{"key":"10.1016\/j.arr.2021.101339_bib0065","series-title":"Topline Result for First DIAN-TU Clinical Trial: Negative on Primary","author":"DIAN-TU_Clinical_Trial","year":"2020"},{"key":"10.1016\/j.arr.2021.101339_bib0070","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3389\/fneur.2015.00207","article-title":"Anti-abeta autoantibodies in amyloid related imaging abnormalities (ARIA): candidate biomarker for immunotherapy in Alzheimer\u2019s disease and cerebral amyloid angiopathy","volume":"6","author":"DiFrancesco","year":"2015","journal-title":"Front. Neurol."},{"key":"10.1016\/j.arr.2021.101339_bib0075","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2021.101339_bib0080","article-title":"EMERGE and ENGAGE topline results: two phase 3 studies to evaluate aducanumab in patients with early Alzheimer\u2019s disease online PP","author":"EMERGE\/ENGAGE_Investigators","year":"2019","journal-title":"Presentation"},{"key":"10.1016\/j.arr.2021.101339_bib0085","series-title":"Early Alzheimer\u2019s Disease: Developing Drugs for Treatment Guidance for Industry","author":"FDA","year":"2018"},{"key":"10.1016\/j.arr.2021.101339_bib0090","doi-asserted-by":"crossref","first-page":"E53","DOI":"10.25011\/cim.v42i1.32393","article-title":"Safety and efficacy of active and passive immunotherapy in mild-to-moderate Alzheimer\u2019s disease: a systematic review and network meta-analysis","volume":"42","author":"Foroutan","year":"2019","journal-title":"Clin. Invest. Med."},{"key":"10.1016\/j.arr.2021.101339_bib0095","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-018-0343-5","article-title":"Impact of amyloid-beta changes on cognitive outcomes in Alzheimer\u2019s disease: analysis of clinical trials using a quantitative systems pharmacology model","volume":"10","author":"Geerts","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.arr.2021.101339_bib0100","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2019.1424","article-title":"Association of amyloid and tau with cognition in preclinical alzheimer disease: a longitudinal study","author":"Hanseeuw","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2021.101339_bib0105","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.arr.2021.101339_bib0110","series-title":"Doing Meta-Analysis in R: A Hands-On Guide","author":"Harrer","year":"2019"},{"key":"10.1016\/j.arr.2021.101339_bib0115","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1136\/jnnp.2006.109074","article-title":"Measuring cognitive change in older adults: reliable change indices for the Mini-Mental State Examination","volume":"78","author":"Hensel","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.arr.2021.101339_bib0120","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","article-title":"How to include multiple groups from one study","author":"Higgins","year":"2011"},{"key":"10.1016\/j.arr.2021.101339_bib0125","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of Solanezumab for mild dementia due to Alzheimer\u2019s disease","volume":"378","author":"Honig","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2021.101339_bib0130","article-title":"Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019","author":"Knopman","year":"2020","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.arr.2021.101339_bib0135","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.biopsych.2005.09.014","article-title":"Size of treatment effects and their importance to clinical research and practice","volume":"59","author":"Kraemer","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.arr.2021.101339_bib0140","doi-asserted-by":"crossref","first-page":"142","DOI":"10.14283\/jpad.2020.26","article-title":"Editorial: an industry perspective: future of anti-amyloid trials","volume":"7","author":"Kramer","year":"2020","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101339_bib0145","doi-asserted-by":"crossref","DOI":"10.1007\/s13311-020-00853-2","article-title":"Immunotherapies for aging-related neurodegenerative diseases-emerging perspectives and new targets","author":"Kwon","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.arr.2021.101339_bib0150","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/acn3.469","article-title":"Efficacy and safety of anti-amyloid-beta immunotherapy for Alzheimer\u2019s disease: a systematic review and network meta-analysis","volume":"4","author":"Mo","year":"2017","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.arr.2021.101339_bib0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.arr.2021.101339_bib0160","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.arr.2021.101339_bib0165","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","article-title":"A critical appraisal of amyloid-beta-targeting therapies for Alzheimer disease","volume":"15","author":"Panza","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.arr.2021.101339_bib0170","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s11481-016-9722-5","article-title":"Safety and efficacy of anti-amyloid-beta immunotherapy in Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"12","author":"Penninkilampi","year":"2017","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.arr.2021.101339_bib0175","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3233\/JAD-160122","article-title":"Amyloid-Related Imaging Abnormalities (ARIA) in immunotherapy trials for Alzheimer\u2019s disease: need for prognostic biomarkers?","volume":"52","author":"Piazza","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2021.101339_bib0180","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1523\/JNEUROSCI.4337-04.2005","article-title":"Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta","volume":"25","author":"Racke","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2021.101339_bib0185","article-title":"Open Peer Commentary to \u201cFailure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019\u201d","author":"Sabbagh","year":"2020","journal-title":"Alzheimer Dement."},{"key":"10.1016\/j.arr.2021.101339_bib0190","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2021.101339_bib0195","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1474-4422(19)30480-6","article-title":"A resurrection of aducanumab for Alzheimer\u2019s disease","volume":"19","author":"Schneider","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.arr.2021.101339_bib0200","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/jnnp-2011-300881","article-title":"What is the clinically relevant change on the ADAS-Cog?","volume":"83","author":"Schrag","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.arr.2021.101339_bib0205","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.arr.2021.101339_bib0210","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.arr.2021.101339_bib0215","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"key":"10.1016\/j.arr.2021.101339_bib0220","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.biopsych.2017.08.010","article-title":"Anti-amyloid-beta monoclonal antibodies for Alzheimer\u2019s disease: pitfalls and promise","volume":"83","author":"van Dyck","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.arr.2021.101339_bib0225","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13195-016-0189-7","article-title":"Bapineuzumab for mild to moderate Alzheimer\u2019s disease in two global, randomized, phase 3 trials","volume":"8","author":"Vandenberghe","year":"2016","journal-title":"Alzheimers Res. Ther."}],"container-title":["Ageing Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163721000866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163721000866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:56:32Z","timestamp":1761591392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568163721000866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":45,"alternative-id":["S1568163721000866"],"URL":"https:\/\/doi.org\/10.1016\/j.arr.2021.101339","relation":{},"ISSN":["1568-1637"],"issn-type":[{"value":"1568-1637","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of monoclonal antibodies against amyloid-\u03b2 on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Ageing Research Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arr.2021.101339","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101339"}}